

Resources

For health care professionals

[Biosimilars in the EU: Information Guide for Healthcare Professionals](#)

[CADTH Biosimilar Drugs: Health care provider hand-out](#)

[FDA Biosimilars: Health care provider materials](#)

[Health Canada – Biosimilar biologic drugs in Canada: Fact Sheet](#)

[International Coalition of Medicines Regulatory Authorities – Biosimilars Statement](#)

[Pan-Canadian Oncology Biosimilars Initiative](#)

- [Biosimilars – What You Need to Know – for Providers](#)
- [Discussing Biosimilars with Patients: A Resource for Healthcare Providers](#)
- [Biologics and Biosimilars: Information for Healthcare Providers \(Youtube\)](#)

[Patients Experience Evidence Research \(PEER\) – Tools for Practice #236](#)

Supporting evidence

[CADTH International Policies on the Appropriate Use of Biosimilar Drugs](#)

[Cohen HP, et al. Switching reference medicines to biosimilars: A systematic literature review of clinical outcomes. Drugs; 2018:463-478.](#)

[Drug Discontinuation in Studies Including a Switch from an Originator to a Biosimilar Monoclonal Antibody: A Systematic Literature Review](#)

[ECCO: Position Statement on the Use of Biosimilars for Inflammatory Bowel Disease](#)

[Efficacious transition from reference infliximab to biosimilar infliximab in clinical practice](#)

[Non-medical Switch from originator infliximab to biosimilar \(rheumatology\)](#)

[Non-medical switch from originator etanercept to biosimilar \(rheumatology\)](#)

[NOR-SWITCH study: non-medical switching for all indications, originator infliximab to biosimilar](#)

[NOR-SWITCH study: long-term follow-up after switching from originator infliximab to its biosimilar](#)

[Switching to Insulin Glargine Biosimilar](#)

[Similar efficacy and safety between insulin glargine biosimilar and biologic \(Lantus\)](#)

[Alberta College of Family Physicians Tools for Practice #236CADTH Biosimilar Drugs: Health care provider hand-out](#)

[CADTH Biosimilar Drugs: Your Questions Answered](#)

[Canadian Family Physician – Biosimilars versus biologics for inflammatory conditions](#)

[ECCO Position Statement on the Use of Biosimilars for Inflammatory Bowel Disease—An Update](#)

[Switching Reference Medicines to Biosimilars: A Systematic Literature Review of Clinical Outcomes](#)

[Therapeutics Initiative. Biosimilars or Biologics. What's the difference? Therapeutic Letter, Sept-Oct 2019](#)

British Columbia Biosimilars Initiative

[Biosimilars Initiative for Prescribers](#)

[Biosimilars Initiative FAQ for Pharmacists](#)